Business Description
Harvard Bioscience Inc
NAICS : 334516
SIC : 3826
ISIN : US4169061052
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.7 | |||||
Debt-to-EBITDA | -15.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.1 | |||||
Beneish M-Score | -3.12 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.1 | |||||
3-Year EBITDA Growth Rate | 12.1 | |||||
3-Year EPS without NRI Growth Rate | 25.6 | |||||
3-Year FCF Growth Rate | 10.4 | |||||
3-Year Book Growth Rate | -4.7 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.9 | |||||
9-Day RSI | 46.47 | |||||
14-Day RSI | 46.27 | |||||
6-1 Month Momentum % | -24.82 | |||||
12-1 Month Momentum % | -44.5 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.06 | |||||
Quick Ratio | 0.91 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 225.88 | |||||
Days Sales Outstanding | 53.56 | |||||
Days Payable | 51.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | 7.18 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 58.41 | |||||
Operating Margin % | -5.64 | |||||
Net Margin % | -14.57 | |||||
FCF Margin % | 0.18 | |||||
ROE % | -20.42 | |||||
ROA % | -10.62 | |||||
ROIC % | -4.75 | |||||
ROC (Joel Greenblatt) % | -29.87 | |||||
ROCE % | -9.3 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 14.79 | |||||
PS Ratio | 0.97 | |||||
PB Ratio | 1.47 | |||||
Price-to-Free-Cash-Flow | 440 | |||||
Price-to-Operating-Cash-Flow | 23.16 | |||||
EV-to-EBIT | -13.45 | |||||
EV-to-EBITDA | -45.26 | |||||
EV-to-Revenue | 1.4 | |||||
EV-to-FCF | 856.74 | |||||
Price-to-Projected-FCF | 1.09 | |||||
Price-to-Median-PS-Value | 0.77 | |||||
Earnings Yield (Greenblatt) % | -7.44 | |||||
FCF Yield % | 0.17 | |||||
Forward Rate of Return (Yacktman) % | -17.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Harvard Bioscience Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 89.619 | ||
EPS (TTM) (€) | -0.302 | ||
Beta | 0.87 | ||
Volatility % | 39.49 | ||
14-Day RSI | 46.27 | ||
14-Day ATR (€) | 0.070646 | ||
20-Day SMA (€) | 2.105 | ||
12-1 Month Momentum % | -44.5 | ||
52-Week Range (€) | 1.9 - 4.84 | ||
Shares Outstanding (Mil) | 43.62 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Harvard Bioscience Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Harvard Bioscience Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Harvard Bioscience Inc Frequently Asked Questions
What is Harvard Bioscience Inc(FRA:HBI)'s stock price today?
When is next earnings date of Harvard Bioscience Inc(FRA:HBI)?
Does Harvard Bioscience Inc(FRA:HBI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |